Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Continuing to create significant shareholder value
Company overview
Financial review
Conclusions
Appendix
Investing in the business
Investments in organic business
R&D >USD 47bn, CAPEX >USD 6bn 2018-20231
References
Value-creating bolt-ons
>USD 33bn 2018-2023
Substantial
cash
generation
Whilst also creating shareholder value via numerous strategic actions
Jun 2018
Divested consumer
health JV
1. Core R&D and CAPEX actuals. 2. In CHF.
Apr 2019
Spun Alcon
□ NOVARTIS Reimagining Medicine
FINANCIAL PROFILE
Returning capital to shareholders
Consistently growing annual dividend²
>USD 42bn of dividends 2018-2023
No rebasing post Alcon and Sandoz spin-off
Share buybacks
>USD 32bn 2018-2023
New USD 15bn SBB commenced in Jul 2023
Nov 2021
Exited Roche stake
Oct 2023
Spun Sandoz
Novartis Q4 Results | January 31, 2024
28View entire presentation